Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianfei Zhike Fang is a Traditional Chinese Medicine (TCM) herbal formula primarily indicated for the treatment of chronic cough and cough variant asthma (CVA). Its therapeutic mechanism is rooted in the TCM principle of 'astringing the lung' (Lianfei) to arrest cough (Zhike), effectively addressing symptoms of lung deficiency and persistent airway irritation. Research indicates that the formula exerts anti-inflammatory effects by downregulating the expression of Th2 cytokines, such as interleukin-4 (IL-4) and interleukin-5 (IL-5), and reducing serum immunoglobulin E (IgE) levels. These actions contribute to the reduction of airway hyperresponsiveness and the stabilization of mast cells. It is commonly developed and utilized within clinical research frameworks in China, often administered as an oral decoction or concentrated granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lianfei Zhike Fang.